Pharmacogn. Mag.
A multifaceted peer reviewed journal in the field of Pharmacognosy and Natural Products
www.phcog.com | www.phcog.net

ORIGINAL ARTICLE

Salutary Effect of Brucine in Ovalbumin-Induced Allergic Rhinitis: Role of T-Helper 1, T-helper 2 Cytokines, Nuclear Factor-Kappa B, STAT3, and RORC Signaling in Mouse Models

Shuang Cai, Yanping Shi, Jifeng Tian, Xia Li, Hui Ji

Department of Integrated Traditional Chinese and Western Medicine,Xi'an Children's Hospital,Xi'an, 710003, China

Submitted: 23-Nov-2020 Revised: 07-Dec-2020 Accepted: 22-Apr-2021 Published: 24-Jan-2022

ABSTRACT

Background: Allergic rhinitis, a type 2 inflammatory sickness, is mediated by immunoglobulin E in nasal mucosa due to airborne allergens and formed inflammatory infiltrates containing of eosinophils, mast cells, basophils, and T-cells, which escorts the secretion of granule proteins, cytokines, and chemokines, thereby inducing the onset of clinical symptoms. Brucine, an indole alkaloid, it activates anti-inflammation, antitumor, antiproliferative property, and antiangiogenic in a tumor and it is considered for the usefulness in the cure of analgesia, diabetes, anemia, and gonorrhea. Contrariwise, the role of brucine on allergic rhinitis (AR) was unresolved. **Materials and Methods:** Hence, the vital mechanism indispensable for the defending achievement of brucine was discovered by giving ovalbumin (OVA) to mice. BALB/c mice were induced for AR by OVA administration. Brucine and dexamethasone were given before OVA. Nasal physical rubbing, the generation of cytokine response, and histological examination studies were achieved in mice. **Results:** Nasal rubbing and sneezing were enhanced in the brucine group of mice than in the AR group of mice. Above and beyond, the malondialdehyde level was diminished and prevented the signaling of cytosolic STAT3 and NF-κBp65 pathway activation through the modulation of anti-inflammatory cytokines. **Conclusion:** Moreover, brucine abridged signs of augmented goblet cells, vascular congestions in the lamina, elevated ciliary loss, and improved eosinophil filtration in the AR model. Hence, our finding outcomes exposed that brucine has an auspicious tactic meant for immunotherapy in AR disease.

Key words: Allergic rhinitis, brucine, nuclear factor-kappa Bp65, ovalbumin, RORC, STAT3

SUMMARY

- Allergic rhinitis, a type 2 inflammatory illness, is facilitated by immunoglobulin E in nasal mucosa due to airborne allergens and formed an inflammatory infiltrates containing of eosinophil, mast cells, basophils, and T-cells, which monitors the secretion of granule proteins, cytokines, and chemokines, thereby persuading the onset of clinical symptoms
- Brucine applied its salubrious effect by balancing the allergic response by T-helper 1 and 2 cytokines and regulating the pro-inflammatory cytokines, nourishing and preserving the nasal histology, hindering the signaling, and activation of NF-κBp65 and STAT3, caspase-1 as well as RORC transcription factor.



Abbreviations used: AR: Allergic rhinitis; OVA: Ovalbumin; MDA: Malondialdehyde

Correspondence:

Dr. Hui Ji,
Department of Integrated Traditional Chinese and WesternMedicine, Xi'an Children's Hospital, Xi'an, 710003, China.
E-mail: xianchcsujh@sina.com

DOI: 10.4103/pm.pm_511_20

Access this article online
Website: www.phcog.com
Quick Response Code:

INTRODUCTION

Allergic rhinitis (AR), a communal complaint, is robustly coupled to asthma and conjunctivitis. It is generally a prolonged chronic state, which is typically undiagnosed in the primary health-care setup. The common signs of AR are congestion and itching of nose, rhinorrhea and sneezing. A comprehensive medical record of the patient such as physical examination and allergen skin testing is bossy for the confirmation of its diagnosis. Second-generation oral antihistamines and intranasal corticosteroids are the existing strongholds for its management. Allergen immunotherapy is highly suggested as an effective immune-modulating treatment for AR during unsuccessful pharmacologic therapy.[1] The incidence of AR is increasing.[2] The quality of life, sleep, and work performance is being exaggerated by severe AR. Due to the occurrence of a dual condition of rhinitis and asthma, the aggravation of allergen in the upper airways also origins a local inflammatory response in the lower airways.[3,4]

The common provoking allergens disturb infiltration of the nasal lining by inflammatory cells, comprising mast cells, CD4-positive T-cells, B-cells, macrophages, and eosinophils. Cytokines such as interleukin-3 (IL-3), IL-4, IL-5, and IL-13 are released by T-helper 2 cells, thereby persuading the production of Immunoglobulin E from plasma cells. Release of histamine and leukotrienes is arbitrated to cause arteriolar dilation,

Cite this article as: Cai S, Shi Y, Tian J, Li X, Ji H. Salutary effect of brucine in ovalbumin-induced allergic rhinitis: Role of T-helper 1, T-helper 2 cytokines, nuclear factor-kappa B, STAT3, and RORC signaling in mouse models. Phcog Mag 2021;17:900-6.

improved vascular permeability, itching, rhinorrhea, mucous secretion, and contraction of lungs smooth muscle due to crosslinking of immunoglobulin E (IgE) bound to mast cells by allergens.[2,3] The early phase of an allergic immune response is mediated by cytokine release followed by the episode of the late-phase inflammatory response in AR, happening 4–8 h after allergen incision and cellular inflammatory response that continues to recurrent symptoms like nasal congestion that happens often.[2,5] The T-helper 1 (Th1) and Th2 cells' upregulation and downregulation are authoritative for immune homeostasis, and the imbalance in Th1/Th2 leads to autoimmune disease and allergic illnesses. This Th1 and Th2 paradigm has been extensively recognized for the past two decades. Upregulation of mRNA expression of GATA3 and RORC and downregulation of expression of Foxp3 might take an imperative place in the pathogenesis of AR and both GATA3 and RORC may be thoroughly linked with the production of IgE.[6]

Brucine, an indole alkaloid present in seeds of *Strychnos nux-vomica* L. (Loganiaceae), is a traditional medicinal herb native to India, Southeast Asia, and northern Australia.[7] Brucine could aggravate anti-inflammation, antitumor, and antiproliferation effects and is valuable for the treatment of analgesia, diabetes, anemia, and gonorrhea.[7,8] Brucine has an inhibitory effect on tumor angiogenesis[7,8] and keeps vasculogenic mimicry activity which might be due to the reduced erythropoietin-producing hepatocellular carcinoma-A2 and matrix metalloproteinase-2 and metalloproteinase-9.[9] Brucine was described to downregulate ERK1/2 and AKT, and it inhibited colon cancer intervention.[10] Brucine immune nanoparticles meaningfully ameliorated the growth, adhesion, invasion, and metastasis of SMMC-7721 cells and it applied as a novel drug carrier system and a probable targeting treatment module for liver cancer.[11] Hence, our objective was to inspect the antiallergic properties of brucine using a mouse model of ovalbumin (OVA)-induced AR to learn the role of brucine on the regulation of nuclear factor-kappa B (NF-κB) signaling and STAT3 pathway. Besides, this study appraised whether brucine regulates the malondialdehyde (MDA), pro-inflammatory cytokines, and Th1/Th2/Th17 cytokines and put forth a therapeutic consequence in AR-induced mouse models.

MATERIALS AND METHODS

Brucine, OVA, and histamine were acquired from Sigma-Aldrich. Cytokine quantitation kits were secured from BD Biosciences, USA. ELISA kits were acquired from Invitrogen, Camarillo, CA.

Experimental mice

Six-week-old male BALB/c mice (26 g) were obtained. Then, the mice were permissible for acclimatization and preserved them in an air-conditioned room based on light/dark cycle (12:12 h) and they were allowable freely for food and water intake. The protocols complicated in this study were allowed by the animal ethics board of our institution.

The mice were isolated into five groups with eight animals in every group:

The segregated mice groups were defined as follows:

Normal control group (Group I) – The mice were disputed intranasally with PBS in a vague manner.

AR-induced group (Group II) – OVA alone-induced group. On days 1, 5, and 14, the mice were replied by intraperitoneal injection with 100 μg of OVA liquefied with 100 μl phosphate-buffered saline (PBS) containing 20 mg aluminum hydroxide as a firming substance. On days 21, 22, and 23, the mice were challenged by intranasal inhalations with 1.5 mg of OVA in 2 μl PBS once a day.

Treatment group (Group III) – OVA-induced + brucine-treated group (10 mg/kg). Brucine was orally administered at a dose of 10 mg/kg body weight 1 h prior to the OVA dispute. On days 1, 5, and 14, the mice were answered by intraperitoneal injection with 100 μg of OVA liquefied with 100 μl PBS comprising 20 mg aluminum hydroxide as a strengthening substance. On days 21, 22 and 23, the mice were opposed by intranasal inhalations with 1.5 mg of OVA in 2 μl PBS once a day.

Treatment group (Group IV) – OVA-induced + brucine-treated group (20 mg/kg). Brucine was orally administered at a dose of 20 mg/kg body weight 1 h before the OVA quarrel. On days 1, 5, and 14, the mice were replied by intraperitoneal injection with 100 μg of OVA liquefied with 100 μl PBS containing 20 mg aluminum hydroxide as a strengthening substance. On days 21, 22, and 23, the mice were opposed by intranasal inhalations with 1.5 mg of OVA in 2 μl PBS once a day.

Positive control group (Group V) – OVA + dexamethasone (DEX) (2.5 mg/kg) group. DEX (2.5 mg/kg) was intraperitoneally given as a positive control 1 h prior to the OVA dispute. On days 1, 5, and 14, the mice were replied by intraperitoneal injection with 100 μg of OVA liquefied with 100 μl PBS containing 20 mg aluminum hydroxide as a strengthening substance. On days 21, 22, and 23, the mice were challenged by intranasal inhalations with 1.5 mg of OVA in 2 μl PBS once a day.

Sensitization and treatment

Sensitization was performed thrice (at 1st, 5th, and 14th days) via injecting 100 μg OVA intraperitoneally emulsified with PBS (100 μl, PBS) with the presence of 20 mg of aluminum hydroxide. The intranasal contests were done using 1.5 mg OVA in 2 μl of PBS. Negative controls were confronted intranasally with PBS in a comparable manner. Brucine (10 and 20 mg/kg), DEX (2.5 mg/kg), and the control vehicle were administered orally with distilled water before OVA intranasal challenge on the 15th and 24th days.

Nasal symptom evaluation

The mice were intranasally administered with OVA, later the nasal indications were calculated 2 min soon after through the prompt counting of nasal sneezing as well as rubbing actions around 10 min. This method was achieved from the 21st day around 10 days. All the experimental mice were deadened using sodium pentobarbital 3 h after the last opinion. The blood sample was collected through cardiac puncture; also, the nasal mucosa, as well as tissue, was detached and then kept at − 20°C until use.

Measurement of total immunoglobulin E in serum

IgE is the vital inflammatory mediators released to inspire the immune response. The evaluation of IgE in the serum was achieved directly after OVA administration. The concentrations were planned as per the instructions, and procedures are given in the ELISA kit.

Histamine release assay

The release of histamine was used for the calculation of mast cell degranulation. For this assay, the supernatant of sensitized cells was centrifuged at 10,000 g in 4°C for 10 min, supernatants were composed, and later, the substance of histamine was planned as per ELISA kit protocol.

Detection of malondialdehyde

This assay is carried out as per the Esterbauer *et al.* method in lung tissues. The supernatant was regulated via sonication by using PBS; trichloroacetic acid (TCA)-butylated hydroxytoluene was added to precipitate proteins and centrifuged at 1000 g for 10 min at 4°C. Later, the supernatant (400 μl) was mixed with HCl (0.6 M; 80 μl) as well as 320 μl thrombin-binding aptamer was dissolved in Tris. The mixture

was kept warming at 80°C for around 10 min, and the absorbance was measured at 530 nm.

Analysis of caspase activity

The level of caspase activity in the serum of control and OVA-induced AR mice was inspected by using the caspase activity assay kit as per the guidelines of manufacturer (Abcam, USA). The absorbance was restrained at 400 nm.

Evaluation of the cytokines

Cytokine quantification kits were used to measure the level of the cytokine such a tumor necrosis factor-α (TNF-α), IL-1β, IL-17A, IL-5, IL-6, IL-10, IL-12, interferon-gamma (IFN-γ), RORc, NF-κBp65, IκB, pNF-κBp65, IκB, STAT3, and pYSTAT3 as per protocol. In brief, the supernatants with standard were distorted into monoclonal antibodies precoated 96-well plates then kept for incubation around 2 h at RT. Following washing with buffer, the secondary antibody was added and mixed into each well and then incubated at RT around 1–2 h. After the removal of secondary antibody and systematic washing, the enzymatic reactions were carried out through the substrate addition and further kept for incubation around 30 min at a dark place. The reactions were accomplished by adding the stop solution; finally, the absorbance was evaluated at 450 nm in an ELISA reader.

Histological examination

After 24 h of last intranasal challenge, all groups of experimental animals were slayed by giving an intraperitoneal injection of pentobarbital at 80 mg/kg and 100 mL of 0.9% physiological saline was perfusion followed by 400 mL of formaldehyde familiarized through the left ventricle. The tissues were fixed in 10% of buffered formalin, kept for 3 days, then permit it to decalcify by keeping in 5% TCA for 7 days. The transversely sectioned nasal cavity at the level of the incisive papilla of the hard palate was then entrenched in paraffin. Sections meant for tissue histology were stained with hematoxylin and eosin whereas the sections to highlight the goblet cells were stained with Alcian blue and periodic acid–Schiff reagent. Digital images were observed from both stained sections using a model DP71 camera (Olympus Optical, Tokyo, Japan) attached to an (Olympus Optical Co. Ltd., Tokyo, Japan) at x40. Images were handled with the[12-14] change in histological morphology was calculated and scored as follows:

No deviation in morphology was scored as 0, mild adjustment was scored as 1, moderated modification of morphology was scored as 2, and severe modification in tissue architecture was scored as 3.

Histological examinations were detected under the microscope by two histopathologists who were heedless of the experimental groups.

Statistical analysis

The results were examined using SPSS software 15.0 (SPSS, Chicago, IL) using one-way ANOVA followed by *post hoc* Dunnett's T3 multiple tests. The results were signified as the mean ± standard deviation of liberated experimental groups. $P < 0.05$ was measured significant at 95% confidence level.

RESULTS

Figure 1 portrays the rubbing and sneezing scores of the control and OVA-induced experimental groups of mice. The scores of nasal sneezing and rubbing were intended on the 28th day for 15 min after the intranasal administration of OVA. In our study, OVA-induced AR mice displayed raised scores for rubbing and sneezing compared to control mice. Administration of brucine imperatively abridged ($P < 0.05$) the scores of rubbing and sneezing in a dose-dependent manner than the OVA-induced group. Likewise, the DEX treatment caused a noteworthy reduction in rubbing and sneezing scores than the OVA-induced AR group.



Figure 1: Brucine inhibited the ovalbumin-induced allergic nasal symptoms of rubbing score and sneezing score. Values are expressed in mean ± standard deviation #$P < 0.001$ compared with the normal group, *$P < 0.05$ compared with the allergic rhinitis control group

Figure 2 signifies the immunoglobulin G (IgG1), IgG2, IgE, and histamine levels in serum of the control and OVA-induced experimental groups of mice. IgE level was augmented due to OVA sensitization, whereas oral administration of brucine knowingly diminished ($P < 0.05$) the level of IgE secretion than control and OVA alone-treated mice dose dependently. A nasal allergen causes sneezing and nose rubbing due to the release of histamine. In this study, there was a distinguished modification in the level of histamine that was found in the OVA alone-treated group. However, brucine unusually exhausted the level of histamine release than the OVA-induced AR group.

Figure 3 exemplifies the serum levels of MDA in the control and OVA-induced experimental groups of mice. MDA level was augmented in the OVA alone-treated group when compared to the control group. Administration of brucine caused a diminution in MDA level by dipping oxidative stress.

Figure 4 displays the NF-κBp65 and IκBα activity in the control and OVA-induced experimental groups of mice. The anti-inflammatory activity of brucine was considered by evaluating the phosphorylation of NF-κBp65 and IκBα. In this present examination, the fallouts presented OVA administration importantly upregulated the expression pattern of phosphorylation of NF-κBp65 and IκBα, whereas the brucine administration meaningfully lessened the NF-κBp65 and IκBα phosphorylation in OVA-induced mice. Then, the IL-1β and TNF-α secretion were assessed to study the pro-inflammatory events and also we found that the inflammatory cytokines were extremely regulated in OVA-induced mice. Brucine administration brought the downregulation of inflammatory cytokines dose dependently. On analyzing the results of these verdicts, it could be inferred that brucine could able to conquer the NF-κBp65 expression and the cytokines involved in inflammatory reactions thereby brucine might constrain the translocation of NF-κBp65 from the cytoplasm into the nucleus.

Figure 5 designates the levels of STAT3, p-YSTAT3, and RORc in the control and OVA-induced experimental groups of mice. The effect of brucine on the STAT3 pathway and their related cytokines were also projected in the current examination. The cytosolic levels of STAT3 and p-YSTAT3 and RORc were definitely improved in OVA-induced AR mice than the control group. On the other hand, the brucine treatment strikingly condensed the STAT3, pYSTAT3, and RORc levels than the OVA alone-treated group. Our findings recognized that the expression of active STAT3 was exhausted in the cytosol in brucine-treated mice and further it infers that the brucine could have inhibited the phosphorylation



Figure 2: Effect of brucine on histamine concentration and immunoglobulin G and immunoglobulin E concentration. Values are expressed in mean ± standard deviation #$P < 0.001$ compared with the normal group, *$P < 0.05$ compared with the allergic rhinitis control group



Figure 3: Oxidative stress marker reducing effect of brucine in control and experimental animals. Values are expressed in mean ± standard deviation #$P < 0.001$ compared with the normal group, *$P < 0.05$ compared with the allergic rhinitis control group



Figure 4: Brucine suppressed the phosphorylation of nuclear factor-kappa Bp65/IκBα signaling and related-cytokines. Values are expressed in mean ± standard deviation #$P < 0.001$ compared with the normal group, *$P < 0.05$ compared with the allergic rhinitis control group



Figure 5: Brucine suppressed STAT3 phosphorylation step and inhibited the STAT3 signaling-related inflammatory cytokines. Values are expressed in mean ± standard deviation #$P < 0.001$ compared with the normal group, *$P < 0.05$ compared with the allergic rhinitis control group

of STAT3 tyrosine and the transcription factor RORc, abridged levels of pro-inflammatory cytokine IL-17A, and their related Th2 cytokines such as IL-5 and IL-6 which are radically augmented in OVA-induced mice. Furthermore, the Treg-related cytokines IL-10 and Th1-associated cytokines IFN-γ and IL-12 were weakened in OVA-insulted mice. Brucine treatment importantly upregulated the cytokines levels in a dose-independent manner than the OVA-induced group.

Figure 6 proves the status of caspase-1 activity in control and OVA-provoked experimental animals. It was exposed that the caspase-1 activity level was extremely raised in the OVA-induced AR mice when compared the control. Remarkably, the brucine (10 and 20 mg/kg)-treated OVA-induced AR mice naked the reduced level of caspase-1 activity. Similarly, the standard drug DEX treatment also condensed the caspase-1 activity in the OVA-induced AR mice.

Figure 7 signifies the histological variations in the control and OVA-induced experimental groups of mice. The nasal mucosa of the OVA-induced mice presented histological amendments in ciliary loss, augmented goblet cells, alterations in vascular congestion, and enlarged infiltration of eosinophils as compared with the normal mice. Brucine (10 and 20 mg/kg) treatment abridged eosinophil infiltrations, ciliary loss, restored the alteration of goblet cells, and vascular congestion. Treatment with standard drug DEX indicated protection and condensed eosinophil infiltrations in the OVA-induced AR group.

DISCUSSION

The reduction of nasal rubbing and sneezing in brucine administered mice recommended its possible valuable efficacy in AR. Further, the anti-inflammatory property was obvious from IgE and IgG levels in brucine-treated mice.

AR is measured as a type I allergic disease which includes adaptive immune response mediated by IgE. Generation of IgE takes place by the interface of T-cells, B-cells, basophils, and mast cells. In addition to this, IgE is secreted by the surface and adhesion molecule's participation and to create an interface of B-cells and T-cells physically.[15] Th2 cells[16] and a decrement of T-regulatory cell responses[17] compel IgE synthesis and the accessory cells. The influx of Th2 cells and eosinophils and the generation of IL-4, IL-5, and IL-13 are the imperative factors of AR.[18]

The early-phase effect of AR ascend in a very little time of experience to the allergen, it leads to the workforce of degranulation of mast cell followed by cross-linking of the membrane-bound IgE. Then, secretion of histamine motivates the early-phase symptoms such as sneezing, itching, and runny nose.[19-21] However, brucine caused a diminution of IgE, IgG1, IgG2a, and histamine levels which are augmented in OVA administered AR mice, thereby deliberating its role in dipping the allergic reaction cascade at the previous phase.

The improving effect of brucine on oxidative stress of OVA-induced AR was considered by measuring MDA levels. MDA is the most copious among the reactive aldehydes derived from lipid peroxidation. It has been recommended that these aldehydes are released from the cell membrane and surge the risk of AR not only by disturbing endothelial cells, nasal and airway mucosa's via oxidative modification of cellular components.[22] In the current examination, brucine depleted the level of MDA, thereby demonstrating its antioxidant activity.

Signaling of NF-κB and IκB are occupied in the enlargement of the typical pathway of inflammation. As per the earlier studies, the induction of cells with TNF-α or IL-1β accordingly stimulated a conformational change in the NF-κB subunit p65.[23] In endothelial cells, the impact of TNF-α forms a basis for the activation of NF-κB and phosphorylation of IκB.[24] In concurrence with the earlier studies, our results stated that the expression of TNF-α and IL-1β was increased in mice exposed to OVA beside a rise in the activation of NF-κBp65. However, brucine given mice covered the cytoplasmic NF-κBp65 activation and contributes to the pro-inflammatory cytokines IL-1β and TNF-α inhibition.

The newest verdicts defined that STAT3 expression in T-cells is energetic to the progression of inflammation in allergic conditions. Activation of STAT3 takes place by the differentiation of Th2 cells and the presence of STAT3 activation inspires the production of Th2 cytokines.[25] In general, STAT3 happens as inactive in cell cytoplasm. IL-6 gene was activated after the episode of STAT3 activation and nuclear translocation of STAT3.[26] Furthermore, STAT3 and RORc are serious necessities for Th17 cell differentiation.[27,28]

In this current study, the total STAT3 and pYSTAT3 were investigated. Our results exemplified that brucine depleted the total STAT3 and inhibited the p-YSTAT3 step. Besides this, the Th2- and Th17-related cytokines comprising IL-5, IL-6, IL-10, RORc, and IL-17A are augmented in OVA-induced AR mice. Brucine prohibited the phosphorylation of STAT3 reaction and choked the STAT3 signaling-related inflammatory cytokines. The level of total STAT3 in the cytoplasm was high in OVA-exposed mice and low in brucine given mice and p-YSTAT3 was also obstructed in brucine treatments. The declined Th2, Th17 cytokines and the augmented Th1 cytokines in the brucine groups proposed the Th1/Th2 balancing activity of brucine. This study data disguised that the fortification against phosphorylation of STAT3 in the cytoplasm, prevention of STAT3 activation, and translocation into nucleus might be presented by brucine via suppressing the production of Th2 and Th17 inflammatory cytokines Moreover, both IL-6 and IL-10 cytokines hold receptors that recruit Janus kinases and activate STAT3 transcription factors.[29] IL-6 leads to the activation of STAT3 tyrosine residue phosphorylation,[30] and the nuclear translocation of active STAT3 befalls and excites the expression of the IL-6 gene.[26] At the same time, IL-10 synthesis is downregulated because of abridged STAT3 activation.[31]

When the phosphorylation of STAT3 was obstructed, STAT3 could not translocate into the nucleus hence could not cooperate with NF-κB. The STAT3 and NF-κB activation and interaction are imperative for the regulation of inflammatory cells.[32] In this present study, brucine downregulates the expressions of NF-κBp65 and STAT3 in the cytoplasm by inhibiting the phosphorylation. Based on these consequences, the infiltration of inflammatory cells and the morphology of nasal histology were changed on brucine administrations. Afterward, the correlation of the results suggested that brucine administration presented protection against inflammation induced by OVA by repressing the activation of NF-κBp65 and STAT3 signaling.



Figure 6: Effect of brucine on caspase-1 activity in control and experimental animals. Values are expressed in mean ± standard deviation #*P* < 0.001 compared with the normal group, **P* < 0.05 compared with the allergic rhinitis control group



Figure 7: Histological alterations of ciliary loss, goblet cells, alterations in vascular congestion, and eosinophil infiltration in control and experimental animals. Values are expressed in mean ± standard deviation #*P* < 0.001 compared with the normal group, **P* < 0.05 compared with the allergic rhinitis control group

Caspase-1, a pro-inflammatory cysteine protease, is responsible for the development and secretion of mature inflammatory cytokines such as IL-1β and IL-18 from immature inflammatory cytokines. The activated caspase-1 contributes in the maturation of IL-1β from immature pro-IL-1β.[33] The functional form of caspase-1 is crucial for the formation of mature IL-1β from cleavage of pro-IL-1β.[34] For instance, Casp1-/-mice defied with OVA displayed a reduction in inflammatory responses of the airway as compared to normal mice.[35] Reliably, in this study, there was an increase in the activity of caspase-1 which was detected in OVA-induced AR mice. On the contrary, brucine-administered mice knowingly dropped caspase 1 activity due to its inhibitory property on the inflammatory pathway.

Earlier studies elucidated the contribution of Th2, Th17, and Treg cells in the pathogenesis of AR. Prior to the invention of the Th17 subset, Th2 cells or the Th1/Th2 balance were recognized as an important modulation in the pathogenesis of the allergic disease. The invention of Th17 and Treg cells strained the knowledge in the diseases of immunology and AR pathology. In the year 2000, Th17 cells were recognized as the cells which produce IL-17,[36] and in the year 2006, the transcriptional factor RORγt was recognized in mice.[37] Apart from allergic diseases, the foremost roles of th17 cells in autoimmune disease have been sumptuously measured. As reported by past studies, the severe cases of birch allergy displayed elevated serum IL-17 levels that are momentously related with AR clinical symptoms.[38,39]

The RORC expression presented large differences with the severity of AR, indicating the rigorousness of AR which gives to the expression of the transcriptional factors. Another remark is the association of RORC and IgE, which can also be inferred in the milieu of relationship with GATA3. One of the previous studies deliver innovative information about transcription factor activation of a subset of T-cells in AR and upregulated the expression of GATA3 and RORC mRNA and downregulated the Foxp3 expression may contribute a noteworthy part in the pathogenesis of AR.[6] RORC inhibitors may achieve the therapeutic effect of AR by varying the inflammatory factors in AR mice.[40] This study confirmed an increase in the nasal mucosal RORC level in AR mice than the control mice and brucine diminished RORC by correlating it with its IgE dipping antiallergic property.

The late-phase allergic reactions displayed by OVA are also shattered by brucine evident from histological changes. The histological examination fallouts exposed brucine-treated mice presented a diminution in ciliary loss, eosinophil infiltration, goblet cells, and vascular congestion.

CONCLUSION

Finally, we accomplish that brucine employed its salubrious effect by balancing the allergic response by Th1 and Th2 cytokines and regulating the pro-inflammatory cytokines, sustaining and preserving the nasal histology, hindering the signaling, and activation of NF-κBp65 and STAT3, caspase-1 as well as RORC transcription factor. The current examination results powerfully suggested that brucine may deal a confident tactic in the case of immunotherapy in AR.

Acknowledgements

This work was supported by Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, 710003, China.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol 2018;14:51.
2. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol 2010;125:S103-15.
3. Small P, Frenkiel S, Becker A, Boisvert P, Bouchard J, Carr S, *et al.* The Canadian rhinitis working group: Rhinitis: A practical and comprehensive approach to assessment and therapy. J Otolaryngol 2007;36;S5-27.
4. Bourdin A, Gras D, Vachier I, Chanez P. Upper airwayx1: Allergic rhinitis and asthma: United disease through epithelial cells. Thorax 2009;64:999-1004.
5. Lee P, Mace S. An approach to allergic rhinitis. Allergy Rounds 2009;1:1.
6. Mo JH, Chung YJ, Kim JH. T cell transcriptional factors in allergic rhinitis and its association with clinical features. Asia Pac Allergy 2013;3:186-93.
7. Agrawal SS, Saraswati S, Mathur R, Pandey M. Cytotoxic and antitumor effects of brucine on Ehrlich ascites tumor and human cancer cell line. Life Sci 2011;89:147-58.
8. Saraswati S, Agrawal SS. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway *in vitro* and *in vivo*. Cancer Lett 2013;332:83-93.
9. Xu MR, Wei PF, Suo MZ, Hu Y, Ding W, Su L, *et al.* Brucine suppresses vasculogenic mimicry in human triple-negative breast cancer cell line MDA-MB-231. Biomed Res Int 2019;2019:6543230.
10. Luo W, Wang X, Zheng L, Zhan Y, Zhang D, Zhang J, *et al.* Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway. J Cell Mol Med 2013;17:1316-24.
11. Qin JM, Yin PH, Li Q, Sa ZQ, Sheng X, Yang L, *et al.* Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma. Int J Nanomedicine 2012;7:369-79.
12. Salib RJ, Howarth PH. Remodelling of the upper airways in allergic rhinitis: Is it a feature of the disease? Clin Exp Allergy 2003;33:1629-33.
13. Bousquet J, Jacot W, Vignola AM, Bachert C, Van Cauwenberge P. Allergic rhinitis: A disease remodeling the upper airways? J Allergy Clin Immunol 2004;113:43-9.
14. Ercan I, Cakir BO, Başak T, Ozbal EA, Sahin A, Balci G, *et al.* Effects of topical application of methotrexate on nasal mucosa in rats: A preclinical assessment study. Otolaryngol Head Neck Surg 2006;134:751-5.
15. Punnonen J, Aversa GG, Vandekerckhove B, Roncarolo MG, de Vries JE. Induction of isotype switching and Ig production by CD5+and CD10+human fetal B cells. J Immunol 1992;148:3398-404.
16. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004;113:395-400.
17. Allam JP, Novak N. Immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol 2014;14:564-9.
18. Wilson MS, Taylor MD, Balic A, Finney CA, Lamb JR, Maizels RM. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J Exp Med 2005;202:1199-212.
19. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2-8.
20. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445-54.
21. Turner H, Kinet JP. Signaling through the high-affinity IgE receptor Fc epsilon RI. Nature 1999;402 6760 Suppl: B24-30.
22. Sagdic A, Sener O, Bulucu F, Karadurmus N, Özel HE, Yamanel L, *et al.* Oxidative stress status and plasma trace elements in patients with asthma or allergic rhinitis. Allergol Immunopathol (Madr) 2011;39:200-5.
23. Milanovic M, Kracht M, Schmitz ML. The cytokine-induced conformational switch of nuclear factor κB p65 is mediated by p65 phosphorylation. Biochem J 2014;457:401-13.
24. Ashton AW, Ware GM, Kaul DK, Ware JA. Inhibition of tumor necrosis factor alpha-mediated NFkappaB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem 2003;278:11858-66.
25. Stritesky GL, Muthukrishnan R, Sehra S, Goswami R, Pham D, Travers J, *et al.* The transcription factor STAT3 is required for T helper 2 cell development. Immunity 2011;34:39-49.
26. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
27. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, *et al.* T helper 17 lineage

differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28:29-39.

28. Backert I, Koralov SB, Wirtz S, Kitowski V, Billmeier U, Martini E, *et al.* STAT3 activation in Th17 and Th22 cells controls IL-22-mediated epithelial host defense during infectious colitis. J Immunol 2014;193:3779-91.
29. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, *et al.* Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003;170:3263-72.
30. Tadokoro T, Wang Y, Barak LS, Bai Y, Randell SH, Hogan BL. IL-6/STAT3 promotes regeneration of airway ciliated cells from basal stem cells. Proc Natl Acad Sci U S A 2014;111:E3641-9.
31. Maher K, Završnik J, Jerič-Kokelj B, Vasiljeva O, Turk B, Kopitar-Jerala N. Decreased IL-10 expression in stefin B-deficient macrophages is regulated by the MAP kinase and STAT-3 signaling pathways. FEBS Lett 2014;588:720-6.
32. Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res 2015;35:39-46.
33. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011;29:707-35.
34. Shipkowski KA, Taylor AJ, Thompson EA, Glista-Baker EE, Sayers BC, Messenger ZJ, *et al.* An allergic lung microenvironment suppresses carbon nanotube-induced inflammasome activation via STAT6-dependent inhibition of caspase-1. PLoS One 2015;10:e0128888.
35. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-6.
36. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000;165:6107-15.
37. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, *et al.* The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells. Cell 2006;126:1121-33.
38. Ciprandi G, De Amici M, Murdaca G, Fenoglio D, Ricciardolo F, Marseglia G, *et al.* Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy 2009;64:1375-8.
39. Ciprandi G, Fenoglio D, De Amici M, Quaglini S, Negrini S, Filaci G. Serum IL-17 levels in patients with allergic rhinitis. J Allergy Clin Immunol 2008;122:650- 1.e2.
40. Wei PC, Tong L, Li R. Effect of RORC inhibitor on HIF-1α and VEGF in nasal mucosa of allergic rhinitis of mice. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018;53:751-6..